# IRWD catalysts: IRONWOOD PHARMACEUTICALS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/irwd/catalysts

> IRONWOOD PHARMACEUTICALS INC (IRWD) has no upcoming catalysts in this calendar. The latest recorded is the IRONWOOD PHARMACEUTICALS INC earnings report, November 5, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | IRONWOOD PHARMACEUTICALS INC |
| Ticker | IRWD (Nasdaq) |
| SEC CIK | 1446847 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/irwd |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2024 | [Apraglutide topline data readout](https://sec-api.dev/pdufa/apraglutide) | IRWD |  | completed, positive | "In February 2024, we announced positive topline results from our pivotal Phase III clinical" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1446847/000155837025007406/irwd-20250331x10q.htm)) |
| April 25, 2025 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "Ironwood plans to report full first quarter 2025 results in early May." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465925039013/tm2513134d1_ex99-1.htm)) |
| May 7, 2025 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "Pharmaceuticals Reports First Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465925045310/tm2514185d1_ex99-1.htm)) |
| Q3 2025 | [Apraglutide NDA/BLA submission](https://sec-api.dev/pdufa/apraglutide) | IRWD |  | scheduled | "- Initiated rolling NDA submission; on track to be completed in Q3 2025 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465925017774/tm257621d1_ex99-1.htm)) |
| August 7, 2025 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "(Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2025 results and recent business performance." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465925074972/tm2522671d1_ex99-1.htm)) |
| November 10, 2025 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465925108806/tm2530577d1_ex99-1.htm)) |
| Jan 2026 | [LINZESS® (linaclotide) NDA/BLA acceptance](https://sec-api.dev/pdufa/linaclotide) | IRWD | functional constipation | completed | "January 2026, the FDA accepted and granted priority review of a supplemental New Drug Application (sNDA) for LINZESS for the treatment of functional constipation (FC) in patients 2 to 5 years of age." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465926056656/tm267094d1_ex99-1.htm)) |
| Q2 2026 | [Apraglutide trial start](https://sec-api.dev/pdufa/apraglutide) | IRWD |  | scheduled | "- On track to begin site initiations for Phase 3 confirmatory trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) in the second quarter of 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465926056656/tm267094d1_ex99-1.htm)) |
| May 7, 2026 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2026 results and recent business performance." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465926056656/tm267094d1_ex99-1.htm)) |
| August 6, 2026 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465926091625/tm2622244d1_ex99-1.htm)) |
| November 5, 2026 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2026 results and recent business performance update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465926123029/tm2629044d1_ex99-1.htm)) |

## Drugs

- [Apraglutide](https://sec-api.dev/pdufa/apraglutide): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/irwd/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IRWD catalysts: IRONWOOD PHARMACEUTICALS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/irwd/catalysts

```bibtex
@misc{secapidev_companies_irwd_catalysts_20261116,
  title        = {IRWD catalysts: IRONWOOD PHARMACEUTICALS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/irwd/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_irwd_catalysts_20261116","title":"IRWD catalysts: IRONWOOD PHARMACEUTICALS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/irwd/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
